Fractyl Health announced that the primary six-month efficacy data of its pivotal REMAIN-1 study is expected to be available in early Q4 2026.

老虎证券2026/07/15 10:17

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hot on the heels, the company plans to submit a regulatory application to the U.S. Food and Drug Administration (FDA) by the end of the fourth quarter of 2026. This timetable marks an important step forward for the company in advancing its innovative therapy.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Fractyl Health announced that the primary six-month efficacy data of its pivotal REMAIN-1 study is expected to be available in early Q4 2026.

You may also like

Crypto prices